Indaptus Therapeutics, Inc.: 10-Q filed 2021-11-15
What Indaptus Therapeutics, Inc. reported in its quarterly report filed 2021-11-15 (fiscal Q3 2021): 23 published measures, 65 facts as tagged in accession 0001493152-21-028318.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-11-15
- Fiscal period
- fiscal Q3 2021
- Accession
- 0001493152-21-028318 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Indaptus Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 43,859,226 | USD | |
| At 2020-12-31 | 1,777,793 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 38,079,042 | USD | |
| At 2021-06-30 | -1,324,483 | USD | |
| At 2021-03-31 | -829,677 | USD | |
| At 2020-12-31 | -237,701 | USD | |
| At 2020-09-30 | 513 | USD | |
| At 2020-06-30 | 2,016,912 | USD | |
| At 2020-03-31 | 2,690,749 | USD | |
| At 2019-12-31 | 3,210,447 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 41,857,222 | USD | |
| At 2020-12-31 | 1,637,499 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | -3,367,164 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -4,495,064 | USD | 273 |
| 2021-04-01 to 2021-06-30 | -515,479 | USD | 91 |
| 2021-01-01 to 2021-03-31 | -612,421 | USD | 90 |
| 2020-07-01 to 2020-09-30 | -1,542,733 | USD | 92 |
| 2020-01-01 to 2020-09-30 | -2,813,932 | USD | 274 |
| 2020-04-01 to 2020-06-30 | -712,618 | USD | 91 |
| 2020-01-01 to 2020-03-31 | -558,581 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | -7,750,820 | USD | 273 |
| 2020-01-01 to 2020-09-30 | -2,367,598 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | 3,854 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | 47,974,397 | USD | 273 |
| 2020-01-01 to 2020-09-30 | 1,167,129 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | -3,854 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | -12,454,565 | USD | |
| At 2020-12-31 | -7,959,501 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 4,335 | USD | |
| At 2020-12-31 | 1,349 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | 836,456 | USD | 273 |
| 2020-01-01 to 2020-09-30 | 116,872 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | -3,367,991 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -4,510,612 | USD | 273 |
| 2020-07-01 to 2020-09-30 | -1,546,413 | USD | 92 |
| 2020-01-01 to 2020-09-30 | -2,830,713 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 43,854,891 | USD | |
| At 2020-12-31 | 1,731,999 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 5,780,184 | USD | |
| At 2020-12-31 | 2,015,494 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 3,340,766 | USD | |
| At 2020-12-31 | 155,957 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 3,367,991 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 4,510,612 | USD | 273 |
| 2020-07-01 to 2020-09-30 | 1,546,413 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 2,830,713 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 697,674 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 1,578,512 | USD | 273 |
| 2020-07-01 to 2020-09-30 | 1,349,835 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 2,302,883 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 8,133,243 | shares | |
| At 2020-12-31 | 1,944,672 | shares |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-12-31 | 44,445 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 1,397,669 | USD | |
| At 2020-12-31 | 94,500 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 2,670,317 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 2,932,100 | USD | 273 |
| 2020-07-01 to 2020-09-30 | 196,578 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 527,830 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | 868 | USD | 273 |
| 2020-01-01 to 2020-09-30 | 639 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 827 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 15,548 | USD | 273 |
| 2020-07-01 to 2020-09-30 | 3,680 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 16,781 | USD | 274 |
Inspect the source
- Entity
- Indaptus Therapeutics, Inc. / CIK 0001857044
- Captured
- 2026-09-21T17:31:34.871Z
- SEC response SHA-256
2898ea6f398935bcc3ad1a326a712d28e35dd793acb1877cad253f0a74e7c581
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001857044.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))